Irinotecan and carboplatin in relapsed small cell lung cancer

详细信息	查看全文 | 推荐本文 |

• 作者：J. Forrest ; C. R ; all ; K. Lansdell ; S. Earl ; B. Cloos ; D. Hadjiyiannakis
• 关键词：Solvothermal synthesis ; 1D chain ; Cobalt (II) phosphites ; Crystal structure
• 刊名：Lung Cancer
• 出版年：2008
• 期刊代码：187_01695002
• 类别：med
• 出版时间：April 2008
• 卷：60
• 期：Supplement 1
• 页码：S4
• 文件大小：40 K

摘要

From December 2002 to October 2005, 39 patients with previously untreated ED-SCLC were enrolled. Patients were treated with irinotecan (50 mg/m² IV on days 1, 8, and 15) and carboplatin (target AUC = 5 IV on day 1) every 4 weeks for up to six cycles.

Results

Thirty-four patients (87.2%) were male and the median age was 65 years. ECOG performance status was 0–1 in 20 (51.3%) patients and 2 in 19 (48.7%) patients. The median number of chemotherapy cycles was six (range: 1–6 cycles). Thirty-five patients were assessable for response evaluation. The overall response rate was 69.2%(1 CR, 26 PR) under the intent-to-treat analysis. After a median follow-up of 22.7 months, the median time to progression was 6.4 months (95%confidence interval [CI]: 5.7–7.1 months) and median overall survival was 11.0 months (95%CI: 9.9–12.0 months). The estimated 1-year survival rate was 42.5%. In terms of toxicities, Grade 3/4 neutropenia and thrombocytopenia occurred in eight (25.6%) and five (15.4%) patients, respectively. Grade 3/4 non-hematologic toxicities included diarrhea (10.3%), anorexia (7.7%), infection (10.3%), and neutropenic fever (12.8%). There was one treatment-related death due to superimposed infection on the broncho-pleural fistula.

Conclusion

The combination chemotherapy of irinotecan and carboplatin was effective and tolerable in previously untreated ED-SCLC patients.div>div>
direct.com/science?_ob=MImg&_imagekey=B6T9C-4M0S2X1-3-1&_cdi=5111&_user=10&_orig=article&_coverDate=12%2F31%2F2006&_sk=999459996&view=c&wchp=dGLzVlz-zSkzV&md5=56e6ae6ed48be753e72f5a19c827e237&ie=/sdarticle.pdf">direct.com/scidirimg/icon_pdf.gif" alt=""> Purchase PDF (146 K)div>div>

ding=0 cellspacing=0 width="100%">

ding:3px 5px 0px 5px">dirimg/bulletTriang.gif" alt="">

di=B6T9C-4SBHS87-D&_orig=article&_acct=C000050221&_version=1&_userid=10&md5=89e8009a78a89e126b12c9a45499efe5">View More Related Articles

div>dirimg/btn_arrow_up_off.gif','/scidirimg/btn_arrow_down_off.gif','http://www.sciencedirect.com/science')">dirimg/btn_arrow_up_off.gif" id="mlktArrow" alt="" border="0" onmouseover="mlktHover(1,'/scidirimg/sci_dir/')" onmouseout="mlktHover(0,'/scidirimg/')"> <div id="CollabBoxContent">div><div id="articleBody" class="font3"><div class="articleHeaderInner" id="articleHeader">dirimg/clear.gif" width="1" height="10" border="0" alt="">directories=yes,toolbar=yes,menubar=yes,status=yes'); doiWin.focus()">doi:10.1016/S0169-5002(08)70012-6 directories=no,toolbar=no,menubar=no,status=no,width=760,height=570'); helpWin.focus()">dirimg/icon_doi.gif" width="136" height="14" alt="How to Cite or Link Using DOI (Opens New Window)" title="How to Cite or Link Using DOI (Opens New Window)" border="0" align="absmiddle">
Copyright © 2008 Elsevier Ireland Ltd All rights reserved.

Posters, 6th Annual BTOG Meeting, 2008

<div class="articleTitle">

Irinotecan and carboplatin in relapsed small cell lung cancer